Drugs / ATG-F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02267512 | Jul 2012 → Dec 2015 | — | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02267512 ↗ |
| Modality | Protein / enzyme biologic | “Anti-T-lymphocyte Immune Globulin” NCT02267512 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT02267512 ↗ |